Daily Highlights

Preview 14 Total

ISTH 2020 Co-Chair Flora Peyvandi Previews Virtual Congress Program

2020 ISTH Congress Co-Chair Flora Peyvandi gives a sneak peak on what to expect with the virtual congress, and some of the key considerations associated with the migration to a virtual meeting.

Alisa Wolberg Shares Insights From New ISTH Diversity, Equity and Inclusion Task Force

Professor Alisa Wolberg discusses the ISTH Diversity, Equity, and Inclusion Task Force and the importance of the initiative, along with the formulation of a clear statement of enhancing diversity amongst the ranks within the ISTH.

Introducing the First-Ever Virtual Congress of the ISTH

ISTH President Claire McLintock gives some opening remarks and welcome to the ISTH 2020 Virtual Congress.

Discover the ISTH Gene Therapy in Hemophilia Initiative

The ISTH Gene Therapy in Hemophilia Initiative is relatively new to the ISTH. Hear from Co-Chair David Lillicrap to see what the committee has been doing, and has been preparing for.

Co-Editor-in-Chief David Lillicrap Discusses the Role of JTH During the COVID-19 Pandemic

Co-Editor-in-Chief of the Journal of Thrombosis and Haemostasis David Lillicrap speaks about his experiences in his role for the journal, and the evolution of it with the current pandemic.

RPTH Editor-in-Chief Mary Cushman Shares New Initiatives

Research and Practice and Thrombosis and Haemostasis (RPTH) Editor-in-Chief Mary Cushman shares the latest happening with RPTH and how things have evolved since 2019.

Prof. Beverley Hunt O.B.E. Shares Information About the World Thrombosis Day Campaign

Professor Beverley Hunt from King’s College in London shares her perspective about the World Thrombosis Day campaign.

RPTH Names First Editor’s Award Recipient: Olivia Palmer

Research and Practice and Thrombosis and Haemostasis (RPTH) named Olivia Palmer, Ph.D., as the first recipient of the RPTH Editor's Award

JTH Honors Six Early Career Authors With Editors’ Awards

Earlier this year, the Journal of Thrombosis and Haemostasis (JTH) selected six early career investigators as 2020 recipients of the JTH Editors' Awards

ISTH Announces Official ISTH 2020 Virtual Congress Twitter Ambassadors

These esteemed scientific communicators will be tweeting throughout the Congress.

ISTH and the American Heart Association Release Scientific Statement Outlining Venous Thromboembolism Research Priorities

The International Society on Thrombosis and Haemostasis (ISTH) and the American Heart Association (AHA) have released a joint scientific statement titled, “Venous Thromboembolism Research Priorities,” identifying five top priorities for research on venous thromboembolism(VTE).

Claim Your Virtual Delegate Bag With Unique Offers and Promotions

All ISTH 2020 Virtual Congress attendees have access to virtual delegate bags online, featuring important information from industry partners.

ISTH Responds to COVID-19 With Open Access Educational Resources

ISTH is dedicated to transformative scientific discoveries and clinical practices, which have been a priority as the coronavirus pandemic (COVID-19) has spread rapidly around the world

Download and View the ISTH 2020 Abstracts

The ISTH 2020 abstracts are now live and available in a convenient, searchable abstracts directory.

An International Multicenter Study of Bevacizumab for Bleeding in Hereditary Hemorrhagic Telangiectasia (the InHIBIT-Bleed Study)

Hanny Al-Samkari, M.D., of Massachusetts General Hospital in Boston, MA, presented results on systemic bevacizumab for bleeding in hereditary hemorrhagic telangiectasia (HHT) from the InHIBIT-Bleed Study

Complement Regulator Factor H is a Cofactor for Thrombin in Both Pro- and Anticoagulant Roles

Thrombin is central to hemostasis, with both pro- and anticoagulant functions. Interest in interactions between complement and coagulation is increasing.

FXIII Catalyses Histone-Fibrin Crosslinking to Inhibit Fibrinolysis

Histones and DNA released from activated immune cells in the form of extracellular traps play an important role in the response to infection by trapping and killing microbial pathogens. However, this may come at a cost.

Longitudinal Assessment of ADAMTS13 Activity Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic Purpura: Results From the German TTP Registry

Charis von Auer-Wegener of the University Medical Center of the Johannes Gutenberg in Mainz, Germany, presented results from research investigating the role of ADAMTS13 activity in predicting recurrence of immune thrombotic thrombocytopenic purpura, or iTTP

Neutrophil Extracellular Traps and Inflammasomes Form an Inflammatory Circuit Promoting Venous Thrombosis

Joana Campos of the Institute of Cardiovascular Sciences, College of Medical and Dental Sciences at the University of Birmingham, United Kingdom, presented results from research that looked into the bidirectional interactions between inflammasomes and neutrophil extracellular traps (NETs) in the context of murine deep venous thrombosis (DVT)

Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for >2 Years With Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A

Lindsey George, M.D., of the University of Pennsylvania and Children's Hospital of Philadelphia in Philadelphia, PA, presented results on SPK-8011, an investigational gene therapy being developed for the treatment of hemophilia A.

Unraveling the Protective Effects of Factor Xa Inhibition by Rivaroxaban on Atherosclerosis by RNA Sequencing

Posma and team presented research on mice who were administered rivaroxaban and had their RNA isolated from aortic arches.

HAT and HAT RI: Novel Factor VIII Molecules Addressing Patients' Needs

Peter Herbener of Biotest AG in Dreieich, Germany, presented results from research that looked into the development of novel recombinant factor VIII (FVIII) molecules, addressing all major limitations of current FVIII substitution therapy

First in Human Liver Biopsy Study Following Gene Therapy for Hemophilia A

ISTH has created an educational initiative known as Gene Therapy in Hemophilia, which has developed educational resources to learn about gene therapy in hemophilia, improve understanding of the fundamentals, and stay abreast of the latest clinical advances, including safety data, as it relates to gene therapy in hemophilia in a global capacity.

Low α2-plasmin Inhibitor Antigen Levels on Admission Predict Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis

Zsuzsa Bagoly, M.D., Ph.D., of the University of Debrecen in Debrecen, Hungary, stated on Sunday during the Fibrinolysis and Proteolysis virtual session that intravenous thrombolysis by recombinant tissue plasminogen activator (rt-PA) fails to achieve recanalization in a large subset of acute ischemic stroke (AIS) patients, while in approximately 6%-8% of cases, intracerebral hemorrhage (ICH) occurs.

OvCa-Chip: A New Organ-on-a-Chip Experimental Model to Dissect Platelet and Vascular (dys)Function in Ovarian Cancer

Abhishek Jain, Ph.D., of Texas A&M University in College Station, TX, presented results on OvCa-Chip, an ovarian tumor-vessel-blood-flow integrated in vitro biosystem, with the intent of evaluating critical platelet-medicated processes in ovarian cancer.

Exogenous Microparticles Bearing Tissue Factor Improve Outcome After Collagenase-Induced Intracranial Hemorrhage

Intracerebral hemorrhage (ICH) is the most common type of spontaneous hemorrhagic stroke and is the most serious and least treatable form of stroke, and affects approximately 2 million people in the world per year.

CD84 Links T Cell and Platelet Activity in Cerebral Thrombo-inflammation in Acute Stroke

David Stegner, Ph.D., of the University of Würzburg in Germany aimed to assess the potential contribution that CD84 had on infarct growth following experimental stroke. Findings could suggest a pharmacologic target aimed toward managing patients suffering from an ischemic stroke.

Hemostasis vs. Homeostasis: Platelets Are Essential for Preserving Vascular Barrier Function in the Absence of Injury

Shuchi Gupta, Ph.D., of the University of Pennsylvania in Philadelphia, PA, presented her results on the role of platelets, their secretion machinery, and platelet signaling pathways in maintaining homeostasis vascular barrier function by studying changes in vascular permeability in thrombocytopenic and transgenic mice.

RPTH Publishes Illustrated State-of-the-Art Capsules in Conjunction with ISTH 2020

View this unique, visual form of scientific communication

Plan to Attend Supported Symposia and Product Theater Presentations

ISTH 2020 features supported symposia and product theater presentations showcasing the latest diagnostic and therapeutic advances from our industry partners.

Discover a Showcase of Innovation and Technology in the Virtual Exhibition

Don’t miss the ISTH 2020 Virtual Exhibition featuring the latest innovations, products, services and solutions that will help you in your practice.

A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

Pratima Chowdary, M.D., presented Phase I/II safety and efficacy results on FLT180a in hemophilia B (HB) patients. FLT180a is an investigational gene therapy medicinal product candidate that includes AAVS3, a rationally designed capsid designed to deliver higher levels of liver transduction than wild-type adeno-associated virus (AAV), and a codon optimized F9 gene with a gain-of-function mutation.

Higher Incidence of Thrombotic Complications in Hospitalized Patients With SARS-COV-2 Virus Versus Influenza Virus Infections

Studies reported findings of coagulopathy and high incidences of thrombotic complications in hospitalized patients with COVID-19 pneumonia in patients admitted to the intensive care unit (ICU) but, to a lesser extent, also in ward-admitted patients. What is unknown is how the incidence of thrombotic complications in COVID-19 patients compares with that observed in hospitalized patients with other virus infections, including influenza, as some studies suggest that SARS-CoV-2 itself induces a specific procoagulant effect.

Incidence of Venous Thromboembolism in Patients Discharged After COVID-19 Hospitalisation

Matthias M. Engelen of University Hospitals Leuven in Leuven, Belgium, presented late-breaking results evaluating the residual thrombotic risk and incidence of venous thromboembolism (VTE) in patients following hospitalization for COVID-19.

Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients With COVID-19 in the United States

Hanny Al-Samkari, M.D., of Massachusetts General Hospital in Boston, MA, sought through his Late-Breaking Abstract to examine incidence of radiographically confirmed venous thromboembolism (VTE) and major bleeding in a large nationally representative U.S. cohort, evaluate predictors of VTE in critically ill patients with COVID-19, and assess whether therapeutic anticoagulation affects survival.

Non-invasive Early Exclusion of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) After Pulmonary Embolism

Chronic thromboembolic pulmonary hypertension (CTEPH) is considered a potentially curable long-term complication of acute pulmonary embolism (PE), comprising chronic thrombotic obstruction of pulmonary arteries, which triggers small-vessel arteriopathy.

Outcome of DOAC Exposure During Pregnancy (…and the Problem of Event Reporting…)

Jan Beyer-Westendorf of Dresden University Hospital in Dresden, Germany, presented results evaluating pregnancy outcomes after direct oral anticoagulant (DOAC) exposure using data from various sources.

ISTH Presents 2020 Esteemed Career Awards

The ISTH has announced the commendable recipients of the 2020 ISTH Esteemed Career Awards

Platelet Desialylation Affects Bleeding Tendency in Immune Thrombocytopenic Patients

Irene Marini of the University of Tubingen in Tübingen, Germany, and Biotest AG presented results from research that looked to assess the impact of desialylating autoantibodies (AAbs) on the bleeding tendency/manifestations of immune thrombocytopenia (ITP) patients.

The ALK Rearrangement is a Major Risk Factor for Venous and Arterial Thrombosis in Non-Small Cell Lung Cancer

Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients and leads to a significant increase in health care costs. Several risk prediction scores to identify cancer patients at high risk of VTE have been proposed, but their clinical usefulness remains a matter of debate, especially as it relates to non-small cell lung cancer (NSCLC).

Thrombin-PAR1/2 Signaling Axis Modulates TLR3-Mediated Procoagulant, Proinflammatory, and Proadhesive Responses in Vascular Endothelial Cells

Subramaniam and colleagues reported that, using synthetic and endogenous PAR-specific ligands, the thrombin-PAR1/2 signaling axis distinctly regulates poly(I:C)-induced gene expression.

A Novel Neutrophil Extracellular Traps (NETs) Assay Predicts DIC and Stratifies Patients with Sepsis for Anti-IL-8 Therapy

Simon Abrams, Ph.D., of the University of Liverpool in the United Kingdom stated on Monday during the Vascular Biology virtual session that the intent of their study was to establish a novel assay for measuring NETs and to assess its clinical significance.

Characterization of the Protein Profile in Thrombi of Patients With Ischemic Stroke and Identification of Potential Biomarkers as Predictors of Negative Clinical Evolution

After the diagnosis of embolic stroke, patients undergo long diagnostic cascades to determine underlying risk factors and potential pathogenesis to provide the best possible therapy and minimize the risk of recurrent stroke events. Unfortunately, in ~40% of patients, the origin of the stroke is unclear.

PAD4-Dependent Assembly of NLRP3 Inflammasome Promotes NET Formation Resulting in Venous Thrombus Progression

Products of NLRP3 inflammasome activation are suspected to play a role in NETosis, but limited information is known. Patrick Münzer, Ph.D., of Boston Children's Hospital in Boston, MA, and others sought to examine whether or not the NLRP3 inflammasome is implicated in NETosis, contributing to a stenosis model of deep vein thrombosis (DVT).

Ultra High-throughput Screening Assay to Identify New Antiplatelet Drugs with Discriminative Mode of Receptor-dependent Action

Delia Irene Fernández, Ph.D., of Maastricht University in the Netherlands, sought to develop an ultra-high-throughput (UTH) screening assay for finding new inhibitory molecules that differentiate between ITAM-linked receptor and GPCR-induced platelet activation.

Treatment of Heavy Menstrual Bleeding in a Multidisciplinary Young Women's Bleeding Clinic for Adolescents: An Institutional 2-year Experience

Megan Brown, M.D., of Emory University in Atlanta, GA, presented results from a retrospective cohort study, which looked at records of young women seen in the Children's Healthcare of Atlanta Comprehensive Women's Bleeding Disorder clinic from 2018 to 2019. Brown commented that the purpose of her study was to characterize the management of adolescent girls with inherited bleeding disorders.

Daily Highlights

Preview 14 Total

Sunday, July 12 15 Total

Monday, July 13 17 Total

Tuesday, July 14 3 Total

STAY UPDATED